Zujia Wang

机构：Viva Biotech (China) · ORCID：0000-0002-1788-6990

发表论文 8 篇 · 总被引 81 次 · h-index 5

代表论文

• Site-Specific Integration of TRAIL in iPSC-Derived Mesenchymal Stem Cells for Targeted Cancer Therapy (2022 · Stem Cells Translational Medicine · 被引 30)
• Mesenchymal stem cells derived from iPSCs expressing interleukin-24 inhibit the growth of melanoma in the tumor-bearing mouse model (2020 · Cancer Cell International · 被引 20)
• Eg5 UFMylation promotes spindle organization during mitosis (2024 · Cell Death and Disease · 被引 17)
• Mesenchymal Stem Cells Derived from Human Urine-Derived iPSCs Exhibit Low Immunogenicity and Reduced Immunomodulatory Profile (2024 · International Journal of Molecular Sciences · 被引 8)
• Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of ITGA2B Promoter-Driven BDDF8 Gene in Hemophilia A (2022 · International Journal of Molecular Sciences · 被引 6)
• Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8+ T-cell activation (2026 · BMC Medicine)